Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 664

1.

Cognitive impairment in Alzheimer's disease is modified by APOE genotype.

van der Vlies AE, Pijnenburg YA, Koene T, Klein M, Kok A, Scheltens P, van der Flier WM.

Dement Geriatr Cogn Disord. 2007;24(2):98-103. Epub 2007 Jun 26.

PMID:
17596691
2.

Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.

van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, van der Flier WM.

Psychol Med. 2009 Nov;39(11):1907-11. doi: 10.1017/S0033291709005492. Epub 2009 Apr 1.

PMID:
19335933
3.

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D.

Arch Neurol. 2007 Sep;64(9):1306-11.

PMID:
17846270
4.

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.

Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R.

Arch Neurol. 2005 Jun;62(6):975-80.

PMID:
15956169
5.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
6.

Cognitive asymmetries associated with apolipoprotein E genotype in patients with Alzheimer's disease.

Finton MJ, Lucas JA, Rippeth JD, Bohac DL, Smith GE, Ivnik RJ, Petersen RC, Graff-Radford NR.

J Int Neuropsychol Soc. 2003 Jul;9(5):751-9.

PMID:
12901781
7.

Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism.

Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, Hänninen T, Ryynänen M, Riekkinen PJ.

Neurology. 1996 Feb;46(2):413-9.

PMID:
8614504
8.

[Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].

Rosich-Estragó M, Figuera-Terré L, Mulet-Pérez B, Arrufat-Cardús MT, Pascual San Emeterio A, Arbeola-Rigau I, Labad-Alquézar A, Vilella-Cuadrada E.

Rev Neurol. 2004 May 1-15;38(9):801-7. Spanish.

9.

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.

Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.

Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.

PMID:
9850873
10.

Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.

Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ.

J Clin Psychiatry. 2009 Oct;70(10):1379-84. doi: 10.4088/JCP.08m04593. Epub 2009 Jun 30.

PMID:
19573495
11.

Association of apolipoproteins e4 and c1 with onset age and memory: a study of sporadic Alzheimer disease in Taiwan.

Chuang WL, Hsieh YC, Wang CY, Kuo HC, Huang CC.

J Geriatr Psychiatry Neurol. 2010 Mar;23(1):42-8. doi: 10.1177/0891988709351804.

PMID:
20145290
12.

Lower cognitive performance of older football players possessing apolipoprotein E epsilon4.

Kutner KC, Erlanger DM, Tsai J, Jordan B, Relkin NR.

Neurosurgery. 2000 Sep;47(3):651-7; discussion 657-8.

PMID:
10981753
13.

APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.

Martins CA, Oulhaj A, de Jager CA, Williams JH.

Neurology. 2005 Dec 27;65(12):1888-93.

PMID:
16380608
14.

Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study.

Dore GA, Elias MF, Robbins MA, Elias PK, Nagy Z.

Diabetologia. 2009 Dec;52(12):2551-60. doi: 10.1007/s00125-009-1497-2. Epub 2009 Aug 20. Erratum in: Diabetologia. 2009 Dec;52(12):2670.

PMID:
19693485
15.

Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.

Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS.

Arch Neurol. 2005 Mar;62(3):454-9.

PMID:
15767511
16.

Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.

McGuinness B, Carson R, Barrett SL, Craig D, Passmore AP.

Neurosci Lett. 2010 Oct 8;483(1):62-6. doi: 10.1016/j.neulet.2010.07.063. Epub 2010 Aug 1.

PMID:
20678545
17.

Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease.

Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ.

Psychol Aging. 1999 Jun;14(2):295-303.

PMID:
10403716
18.

Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon4: relation to chronological age and recognition memory.

Lind J, Larsson A, Persson J, Ingvar M, Nilsson LG, Bäckman L, Adolfsson R, Cruts M, Sleegers K, Van Broeckhoven C, Nyberg L.

Neurosci Lett. 2006 Mar 20;396(1):23-7. Epub 2006 Jan 6.

PMID:
16406347
19.

APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.

Klages JD, Fisk JD, Rockwood K.

Dement Geriatr Cogn Disord. 2003;15(1):1-5.

PMID:
12457072
20.

Apolipoprotein E and cognitive performance: a meta-analysis.

Small BJ, Rosnick CB, Fratiglioni L, Bäckman L.

Psychol Aging. 2004 Dec;19(4):592-600.

PMID:
15584785

Supplemental Content

Support Center